Literature DB >> 19214569

Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy.

Ioannis Zachos1, Panagiotis A Konstantinopoulos, Gerasimos P Vandoros, Michalis V Karamouzis, Athanasios G Papatsoris, Thomas Podimatas, Antonios Papachristodoulou, Michael Chrisofos, Charalambos Deliveliotis, Athanasios G Papavassiliou.   

Abstract

PURPOSE: We conducted a prospective study to determine whether expression of telomerase reverse transcriptase (hTERT) is associated with recurrence-free-survival (RFS) or development of invasive disease in patients with high risk superficial bladder cancer (SBC) that received adjuvant BCG immunotherapy.
METHODS: Thirty patients with high-grade T1 tumors were evaluated. Pre-BCG TURBT and post-BCG specimens were analyzed for hTERT nucleolar expression by immunohistochemistry.
RESULTS: Post-BCG hTERT expression was statistically significantly lower than pre-BCG hTERT expression. Pre-BCG hTERT nucleolar staining in more than 75% of cells was associated with worse RFS (9 months vs. not yet reached, P = 0.05), while post-BCG hTERT nucleolar staining in more than 50% of the cells was associated with worse RFS (6 months vs. not yet reached, P = 0.001) and development of invasive disease. In multivariate analysis, post-BCG hTERT expression was independently associated with RFS and development of invasive disease.
CONCLUSIONS: Immunohistochemical evaluation of hTERT may help define a subset of high risk SBC patients that will eventually fail BCG and may therefore benefit from early salvage cystectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214569     DOI: 10.1007/s00432-009-0557-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

1.  Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  T Kobayashi; K Kubota; T Takayama; M Makuuchi
Journal:  Am J Surg       Date:  2001-03       Impact factor: 2.565

Review 2.  The reactivation of telomerase activity in cancer progression.

Authors:  J W Shay; W E Wright
Journal:  Trends Genet       Date:  1996-04       Impact factor: 11.639

3.  Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.

Authors:  Hermann Brustmann
Journal:  Gynecol Oncol       Date:  2005-09       Impact factor: 5.482

4.  Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.

Authors:  T Shinka; A Hirano; Y Uekado; T Ohkawa
Journal:  Br J Urol       Date:  1990-07

5.  Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.

Authors:  D L Lamm; J I DeHaven; J Shriver; M F Sarosdy
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

6.  Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.

Authors:  A R Zlotta; J C Noel; I Fayt; A Drowart; J P Van Vooren; K Huygen; J Simon; C C Schulman
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

7.  Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion.

Authors:  Cheryl T Lee; Rodney L Dunn; Collette Ingold; James E Montie; David P Wood
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

8.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

Authors:  H W Herr; D M Schwalb; Z F Zhang; P C Sogani; W R Fair; W F Whitmore; H F Oettgen
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

9.  Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases.

Authors:  David L Smith; Jean-Charles Soria; Luc Morat; Qinghua Yang; Laure Sabatier; Diane D Liu; Rabih A Nemr; Asif Rashid; Jean-Nicolas Vauthey
Journal:  Ann Surg Oncol       Date:  2004-01       Impact factor: 5.344

10.  hTERT protein expression is independent of clinicopathological parameters and c-Myc protein expression in human breast cancer.

Authors:  A E Elkak; G Meligonis; M Salhab; B Mitchell; J R S Blake; R F Newbold; K Mokbel
Journal:  J Carcinog       Date:  2005-10-04
View more
  5 in total

1.  Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG.

Authors:  Ioannis Zachos; Vasileios Tzortzis; Lampros Mitrakas; Michael Samarinas; Anastasios Karatzas; Stavros Gravas; Gerasimos P Vandoros; Michael D Melekos; Athanasios G Papavassiliou
Journal:  Tumour Biol       Date:  2013-12-28

2.  Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?

Authors:  Luís Lima; Mário Dinis-Ribeiro; Adhemar Longatto-Filho; Lúcio Santos
Journal:  Adv Urol       Date:  2012-08-07

3.  Association between the TERT Genetic Polymorphism rs2853676 and Cancer Risk: Meta-Analysis of 76,108 Cases and 134,215 Controls.

Authors:  Jin-Lin Cao; Ping Yuan; Abudumailamu Abuduwufuer; Wang Lv; Yun-Hai Yang; Jian Hu
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

4.  Genetic polymorphisms in TERT are associated with increased risk of esophageal cancer.

Authors:  Yifei Wu; Mengdan Yan; Jing Li; Jingjie Li; Zhengshuai Chen; Peng Chen; Bin Li; Fulin Chen; Tianbo Jin; Chao Chen
Journal:  Oncotarget       Date:  2017-02-07

Review 5.  The prognostic significance of hTERT overexpression in cancers: A systematic review and meta-analysis.

Authors:  Kai Wang; Rui-Ling Wang; Jian-Jun Liu; Ji Zhou; Xue Li; Wen-Wei Hu; Wei-Jian Jiang; Ning-Bo Hao
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.